ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2022
Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 3 syntheses or guidelines pooled it, 134 citations in OpenAlex.
- Blood Biomarkers as Prognostic Indicators for Neurological Injury in COVID-19 Patients: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- GFAP as a Potential Biomarker for Alzheimer's Disease: A Systematic Review and Meta-Analysis.Cells · 2023Pooled it
- Biomarkers in long COVID-19: A systematic review.Frontiers in medicine · 2023Pooled it
- Trajectories of Inflammatory Markers and Post-COVID-19 Cognitive Symptoms: A Secondary Analysis of the CONTAIN COVID-19 Randomized Trial.Neurology(R) neuroimmunology & neuroinflammation · 2024Trial
- Article
- Article
- Increased incidence of mild cognitive impairment in long COVID patients.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Observational
- Impact of nutrition on long COVID.Sports medicine and health science · 2026Review
- Mendelian randomization analyses support causal relationships between COVID-19 and changes in brain structure and function.European archives of psychiatry and clinical neuroscience · 2026Article
- Roles of Reactive Oxygen Species in Relationships Between Viral Infections and Alzheimer's Disease and Related Dementia.Antioxidants (Basel, Switzerland) · 2026Review
- Brain-injury and Alzheimer's disease biomarkers are elevated in patients with suspected infection and physiological derangement: importance for context-specific interpretation of Alzheimer's biomarkers.Brain communications · 2026Article
- Examining neuroimaging biomarkers, plasma biomarkers and cognitive functions in patients with recovered COVID-19 infection: a multicentre study using 7T MRI.Brain communications · 2026Article
- Post-infection brain atrophy accelerates cognitive and molecular changes underlying dementia.Alzheimer's research & therapy · 2025Article
- ITCH regulates Golgi integrity and proteotoxicity in neurodegeneration.Science advances · 2025Article
- Comparison of cerebrospinal fluid biomarkers in patients with severe COVID-19 neurological outcomes and Alzheimer's disease.Brain, behavior, & immunity - health · 2025Article
- Neurocognitive Impairment After COVID-19: Mechanisms, Phenotypes, and Links to Alzheimer's Disease.Brain sciences · 2025Review
- Transcriptomic profiling of severe and critical COVID-19 patients reveals alterations in expression, splicing and polyadenylation.Scientific reports · 2025Article
- Observational
- Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection.Nature medicine · 2025Article
- Viruses and neurodegeneration: a growing concern.Journal of translational medicine · 2025Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
introductionNeurological complications among hospitalized COVID-19 patients may be associated with elevated neurodegenerative biomarkers.
methodsAmong hospitalized COVID-19 patients without a history of dementia (N = 251), we compared serum total tau (t-tau), phosphorylated tau-181 (p-tau181), glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), ubiquitin carboxy-terminal hydrolase L1 (UCHL1), and amyloid beta (Aβ40,42) between patients with or without encephalopathy, in-hospital death versus survival, and discharge home versus other dispositions. COVID-19 patient biomarker levels were also compared to non-COVID cognitively normal, mild cognitive impairment (MCI), and Alzheimer's disease (AD) dementia controls (N = 161).
resultsAdmission t-tau, p-tau181, GFAP, and NfL were significantly elevated in patients with encephalopathy and in those who died in-hospital, while t-tau, GFAP, and NfL were significantly lower in those discharged home. These markers correlated with severity of COVID illness. NfL, GFAP, and UCHL1 were higher in COVID patients than in non-COVID controls with MCI or AD. DISCUSSION: Neurodegenerative biomarkers were elevated to levels observed in AD dementia and associated with encephalopathy and worse outcomes among hospitalized COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.